M.D., Ph.D. Professor Momoko Nishikori
Malignant lymphoma is a malignant tumor derived from mature lymphocytes that has been increasing in Japan in recent years. Since the tumor cells themselves are immune cells, they have various unique and interesting characteristics. Using lymphoma cell lines and lymphoma model mice, we are working in collaboration with the Department of Hematology to elucidate the role of genetic abnormalities in lymphoma cells and to develop treatments that focus on the relationship with the tumor microenvironment.
Publications
- Yuan H. et al. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment. Cancer Sci. 2021;112:4604-16.
- Otsuka Y. et al. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol. 2020;119:35-45.
- Jo. T. et al. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood. 2020;1366:684-97.
- Izumi K, et all. Establishment and characterization of a MALT lymphoma cell line carrying an API2-MALT1 translocation. Genes Chromosomes Cancer 2020;59(9):517-24.
- Arima H, et al. B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell–dominant T-cell responses via IL-33. Blood Adv. 2018:2: 2282–2295.
研究室
Professor：Momoko Nishikori, MD, Ph.D.
E-mail：nishikor@kuhp.kyoto-u.ac.jp
URL：https://hematol.kuhp.kyoto-u.ac.jp/research/lymphoma.html